Apply to trial NCT07270835

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 4Drug trial

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

For patients who met the inclusion criteria, treatment regimens were administered: Rituximab 375 mg/m², intravenously, once weekly for 4 weeks. Zanubrutinib 160 mg, orally, twice daily for 4 weeks. Combined drugs: prednisone 100 mg/m²/d, orally, d1-5; Ruxolitinib 15mg bid orally; With/without emapalumab as appropriate.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening